Metabolic Dysfunction-Associated Steatotic Liver Disease and Sarcopenia: Review of Literature
Journal of Clinical Medicine · 23.02.2026 · 15 (4) · 1661
DOI: 10.3390/jcm15041661 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 23.02.2026. Verfasst von Hiroki Nishikawa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Osaka, Japan. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
In 2023, the terminology of metabolic dysfunction-associated steatotic liver disease (MASLD) was proposed. MASLD uses metabolic abnormalities as an inclusion criterion. On the other hand, sarcopenia is defined by decrease in muscle mass and muscle strength. Skeletal muscle can be affected by insulin resistance (IR), and it is the largest site of insulin-stimulated glucose disposal. In recent years, advances in treatment have extended the life expectancy of patients with chronic liver disease (CLD). Due to the aging population, aging-related primary sarcopenia is expected to increase. On the other hand, liver fibrosis is an important treatment target associated with the onset of serious adverse events and poor prognosis in MASLD. The liver is the central organ for nutrition and metabolism, and patients with CLD may develop secondary sarcopenia due to various nutritional and metabolic disorders unrelated to aging. There is a strong correlation between sarcopenia, muscle fatty degeneration, liver fibrosis and IR in MASLD. MASLD and sarcopenia have a bidirectional relationship, forming a vicious cycle. In this review, we will summarize the relationship between MASLD and sarcopenia based on the current knowledge.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Osaka, Japan.
- Department of Gastroenterology, Kobe Asahi Hospital, Kobe 653-8501, Hyogo, Japan.
- Department of Human Immunology and Translational Research, National Institute of Global Health and Medicine, Japan Institute for Health Security, Shinjukuku 162-0052, Tokyo, Japan.
ORCID-Profile: Hiroki Nishikawa, Soo Ki Kim, Akira Asai
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Nishikawa, H., Kim, S. K., Yoshio, S., & Asai, A. (2026). Metabolic Dysfunction-Associated Steatotic Liver Disease and Sarcopenia: Review of Literature. Journal of Clinical Medicine, 15(4), 1661. https://doi.org/10.3390/jcm15041661
Vancouver
Nishikawa H, Kim SK, Yoshio S, Asai A. Metabolic Dysfunction-Associated Steatotic Liver Disease and Sarcopenia: Review of Literature. Journal of Clinical Medicine. 2026;15(4):1661. doi:10.3390/jcm15041661
BibTeX
@article{Nishikawa2026,
author = {Nishikawa, Hiroki and Kim, Soo Ki and Yoshio, Sachiyo and Asai, Akira},
title = {Metabolic Dysfunction-Associated Steatotic Liver Disease and Sarcopenia: Review of Literature},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {4},
pages = {1661},
doi = {10.3390/jcm15041661}
}
EUVIMED